Food and Drug Administration Approvals

Dermatologic Agents  Accutane  (isotretinoin)
Business:  Roche
Drug Message Confinement:  Supplemental New Drug Action (Approval Date: 11/1/02)
Clinical Summary:  Ware labeling for  Accutane  has been strengthened to clarify those luck in which pregnancy tests and  Accutane  Statement Stickers are applicable.
Substance fact to pediatric patients has been added based on the results of recent studies conducted in this patient role integer.
A content has been added regarding the long-term use of  Accutane  advising that  Accutane  be given at the recommended doses for no longer than the recommended period.
This is a part of article Food and Drug Administration Approvals Taken from "Isotretinoin (Generic Accutane) Information" Information Blog